Thioester prodrugs for the treatment of renal anomalies
AssigneeAltibio, Inc.
InventorsCharles M. COOK, Marc Patrick REICHENBERGER, Shripad BHAGWAT
Life of this patent
Estimating the term…
Abstract
Provided herein are compounds, thioester prodrugs thereof, compositions, and methods for the treatment of diseases and disorders associated with renal anomalies.
Claims47
A compound of the following formula
- wherein R1 is —(C═O)alkyl, —(C═O)alkenyl, —(C═O)alkynyl, —(C═O)cycloalkyl, —(C═O)alkoxyalkyl, —(C═O)heterocyclyl, —(C═O)heterocycloalkyl, —(C═O)aryl, —(C═O)arylalkyl, or —(C═O)heteroaryl;
- wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl are optionally substituted and/or comprise one or more stereogenic centers;
- wherein R1 is not methyl, CH3(CH2)16—, CH3(CH2)14—, CH3(CH2)12—, or CH3(CH2)10—,
- wherein R1 is not phenyl, 2-acetoxyphenyl, 4-nitrophenyl, or 3,4,5-trimethoxyphenyl;
- wherein R1 is not 3-pyridyl;
- wherein R1 is not
- wherein R1 is not
- and
- wherein when R1 is
- then the compound has an ee greater than zero;
- or
- a pharmaceutically acceptable salt thereof.
The compound of any preceding claim, wherein when alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heteroaryl is substituted, then the substituents are selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, amino, halo, cyano, nitro, hydroxy, acyl, amido, —C(O)—, —C(S)—, haloalkyl, and azido.
A compound of the following formula
- wherein R1 is —(C═O)alkyl, —(C═O)alkenyl, —(C═O)alkynyl, —(C═O)cycloalkyl, —(C═O)alkoxyalkyl, —(C═O)heterocyclyl, —(C═O)heterocycloalkyl, —(C═O)aryl, —(C═O)arylalkyl, or —(C═O)heteroaryl;
- wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl are optionally substituted;
- wherein the compound has an ee greater than zero;
- or
- a pharmaceutically acceptable salt thereof.
A method for treating a condition, disease, or disorder in a patient comprising administering to the patient a therapeutically effective amount of a compound of the following formula
- wherein R1 is —(C═O)alkyl, —(C═O)alkenyl, —(C═O)alkynyl, —(C═O)cycloalkyl, —(C═O)alkoxyalkyl, —(C═O)heterocyclyl, —(C═O)heterocycloalkyl, —(C═O)aryl, —(C═O)arylalkyl, or —(C═O)heteroaryl;
- wherein alkyl, alkenyl, alkynyl, cycloalkyl, aryl, and heteroaryl are optionally substituted and/or comprise one or more stereogenic centers;
- and
- wherein when R1 is
- then the compound has an ee greater than zero;
- or
- a pharmaceutically acceptable salt thereof.
A method for treating a kidney disease, a renal disease, a bladder disease, a urinary disease, a ureteral disease, kidney stones, staghorn stones, cystine stones, calculi, lithiasis, nephrolithiasis, urolithiasis, urothiasis, ureterolithiasis, renolithiasis, SLC3A1 gene mutations, SLC7A9 gene mutations, defects in the dibasic amino acid transporter, and cystinuria in a patient comprising administering to the patient a therapeutically effective amount of a compound of the following formula having an ee greater than zero
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.